Drug Trial Radar · NCT04621123
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
Last checked: Nov 20, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
384
Actual
Start
Nov 10, 2020
Primary completion
May 31, 2021
Study completion Jul 28, 2021
Sponsor
- Lead sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Germans Trias i Pujol Hospital; IrsiCaixa; Banc de Sang i Teixits; Grifols Biologicals, LLC
- First posted
- Nov 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID-19 patients who are non-hospitalised. Subjects with confirmed infection by SARS-CoV-2 will receive SMT plus a total of 200-300 mL of convalescent plasma that has been pathogen-inactivated using MBT or placebo. Approximately 474 individuals will be randomized (1:1) with an interim analysis after the first 60 subjects (30 in each arm). The sample size will be re-assessed upon interim analysis. Approximately 135 individuals from selected study sites will be included in the substudy to assess the immune response and the methods of sampling. This is a prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID-19 patients who are non-hospitalised. Subjects with confirmed infection by SARS-CoV-2 will receive SMT plus a total of 200-300 mL of convalescent plasma that has been pathogen-inactivated using MBT or placebo. Approximately 474 individuals will be randomized (1:1) with an interim analysis after the first 60 subjects (30 in each arm). The sample size will be re-assessed upon interim analysis. Approximately 135 individuals from selected study sites will be included in the substudy to assess the immune response and the methods of sampling. The investigational product will be administered by IV infusion at baseline. Participants will continue their standard medical treatment (SMT) for SARS-CoV-2 infection as prescribed by their regular physician. If applicable, SMT may be modified during the study, depending on personal requirements, the severity and progression of the disease, and need for hospitalization. Subjects' participation (from inclusion/baseline visit to the end-of-study visit) will be up to 60 days.
Conditions
- SARS-CoV-2 Infection
- Safety and Efficacy
Interventions
Convalescent anti-SARS-CoV-2 MBT plasmaBiological
Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
Control GroupOther
Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospitalization rate (safety and efficacy)Time frame: Day 28
- SARS-CoV-2 viral load (safety and efficacy)Time frame: Day 7
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitari de Bellvitge
Barcelona, Spain
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
Hospital Sant Bernabé (Hospital de Berga)
Berga, Barcelona, Spain
CUAP Manresa (Planta 0 del CAP Bages)
Manresa, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.